



Figure S2. PBPK simulations of the effects of gemfibrozil (left) and clopidogrel 25 (right) on the plasma concentrations of repaglinide. Individual trials are shown as thin lines, and their means as thick lines. Blue lines represent the placebo phase and grey lines the interaction phase. In the clopidogrel 25 model, the acyl- β -D-glucuronide metabolite has an unbound hepatocyte-to-plasma concentration ratio of 25 and an OATP1B1 K_i of 5.45 μ M.

Circles refer to clinical data from Niemi et al. (2003) and from Tornio et al. (2014).